Loading...
•
Sep 30, 2020
Orthofix Q3 2020 Earnings Report
Reported strong execution and leadership amidst COVID-19 uncertainty, highlighted by sequential global net sales growth.
Key Takeaways
Orthofix reported a net sales of $111.0 million, EPS of $0.24, and adjusted EPS of $0.31 for Q3 2020. The U.S. spinal implants business grew 19% over the third quarter of 2019.
Net sales increased 52% sequentially and were within 2% of 2019 performance.
US Spinal Implants net sales increased 19% over the prior year.
Motion Preservation sales in the U.S. increased 44% sequentially and over 400% over prior year.
Entered into an investment and co-development partnership with Neo Medical SA.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.com Forward Guidance
Due to the uncertainty of the COVID-19 pandemic and its potential effects, the Company is not providing quantitative guidance for the fourth quarter of 2020 at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income